Biosimilars – Forecast – Immunology
In 2024, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in the major market in this therapy area totaled $7 billion. Throughout the 2024-2034 forecast period, an increasing number of branded biologics in the immunology space are set to lose patent protection, and biosimilars will launch, reducing patient share and drug prices of branded biologics. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Immunology
Related Market Assessment Reports
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
